References
- Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et
al. European Association of Urology Guidelines on Non-muscle-invasive
Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol
2019; 76(5): 639-657.
- Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala
E, et al. An individual patient data meta-analysis of the long-term
outcome of randomised studies comparing intravesical mitomycin C
versus bacillus Calmette-Guérin for non-muscle-invasive bladder
cancer. Eur Urol 2009; 56(2): 247-56.
- Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce
recurrence in patients with superficial bladder cancer? A
meta-analysis of randomized trials. Urology 2006; 67(6): 1216-23.
- Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus
mitomycin C in superficial bladder cancer: formal meta-analysis of
comparative studies on tumor progression. Urology 2004; 63(4): 682-6
- Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus
Calmette-Guerin reduces the risk of progression in patients with
superficial bladder cancer: a meta-analysis of the published results
of randomized clinical trials. J Urol 2002; 168(5): 1964-70.
- Temeltas G, Kosova F, Ucer O, Muezzinoglu T, Ari Z. Effects of
Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and
Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and
Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. J
of Urol Surg 2017; 4: 71-75.
- Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, Kamat A. High baseline
levels of interleukin-8 in leukocytes and urine predict tumor
recurrence in non-muscle invasive bladder cancer patients receiving
bacillus Calmette-Guerin therapy: A long-term survival analysis.
Oncoimmunology 2017; 6(2): e1265719.
- Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin
immunotherapy for superficial bladder cancer. J Urol 2003; 170: 964-9
- Takeuchi A, Dejima T, Yamada H, Shibata K, Nakamura R, Eto M, et al.
IL-17 production by gammadelta T cells is important for the antitumor
effect of Mycobacterium bovis bacillus Calmette-Guerin treatment
against bladder cancer. Eur J Immunol 2011; 41: 246-51.
- Ma Y, Ren Y, Dai ZJ, Wu CJ, Ji YH, Xu J. IL-6, IL-8 and TNF-α levels
correlate with disease stage in breast cancer patients. Adv Clin Exp
Med 2017; 26(3): 421-426.
- Mantovani A, Barajon I, Garlanda C. IL-1 and IL-1 regulatory pathways
in cancer progression and therapy. Immunol Rev 2018; 281(1): 57-61.
- Isci Bostanci E, Ugras Dikmen A, Girgin G, Gungor T, Baydar T, Nuri
Danisman A. A New Diagnostic and Prognostic Marker in Endometrial
Cancer: Neopterin. Int J Gynecol Cancer 2017; 27(4): 754-758.
- (**)De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, De
Groot ER, et al. Induction of urinary interleukin-1 (IL-1), IL-2,
IL-6, and tumour necrosis factor during intravesical immunotherapy
with bacillus Calmette-Guérin in superficial bladder cancer. Cancer
Immunol Immunother 1992; 34(5): 306-12.
- (**)Böhle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, et
al. Detection of urinary TNF, IL 1, and IL 2 after local BCG
immunotherapy for bladder carcinoma. Cytokine 1990; 2(3): 175-81.
- Mack D, Gomahr A, Herold M, Frick J. Neopterin as a monitoring
parameter for treatment with BCG in superficial bladder cancer. Eur J
Cancer 1995; 31A(6): 1025-6.
- (*)Hwang EC, Jung SI, Lee HJ, Lee JJ, Kwon DD. Generation of potent
cytotoxic T lymphocytes against in male patients with non-muscle
invasive bladder cancer by dendritic cells loaded with dying T24
bladder cancer cells. Int Braz J Urol 2017; 43(4): 615-627.
- (*)Chen MF, Lin PY, Wu CF, Chen WC, Wu CT. IL-6 expression regulates
tumorigenicity and correlates with prognosis in bladder cancer. PLoS
One 2013; 8(4): e61901.
- (**)Cai T, Nesi G, Mazzoli S, Meacci F, Tinacci G, Luciani LG, et al.
Prediction of response to bacillus Calmette-Guérin treatment in
non-muscle invasive bladder cancer patients through interleukin-6 and
interleukin-10 ratio. Exp Ther Med 2012; 4(3): 459-464.
- Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM,
Anderson R, et al. Cytokine Panel for Response to Intravesical Therapy
(CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts
Patient Response to Bacillus Calmette-Guérin. Eur Urol. 2016; 69(2):
197-200.
- Kumari N, Agrawal U, Mishra AK, Kumar A, Vasudeva P, Mohanty NK, et
al. Predictive role of serum and urinary cytokines in invasion and
recurrence of bladder cancer. Tumour Biol 2017; 39(4): 1-14.
Table 1. Mean IL-1, IL-6, IL-8 and neopterin levels of patient
and control groups.